Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Can Lower Doses of EGFR Inhibitor Therapy Still be Effective?
Please Note: While this is Still Excellent Background Info, New Treatments and Procedures Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

One nagging question that people often ask about, or at least worry about, is whether they are compromising their ability to benefit from an EGFR tyrosine kinase inhibitor (TKI) like Tarceva (erlotinib) or Iressa (gefitinib) if they need to cut down on the dose because of problems with side effects. Anecdotally, I think just about every clinical oncologist believes that is absolutely not the case, based on the fact that many of our patients who have very dramatic and prolonged responses to EGFR inhibitors have also required one or more dose reductions and continue to do very well on a lower dose than the starting dose of Tarceva at 150 mg/day or Iressa at 250 mg/day. We also know from lab-based work that cancer cells with an EGFR mutation are about ten times as sensitive to the effects of EGFR TKIs than cancer cells without an EGFR mutation. This suggests that patients who have an NSCLC tumor with an EGFR mutation may require a lower than standard dose to still receive the benefits. At this year's ASCO meeting, Inoue and colleagues will present a retrospective analysis of outcomes based on dose for patients on their study of standard chemo vs. Iressa for patients with an EGFR mutation detected before starting first line therapy. kobayashi-nej002-trial (click on image to enlarge)

The retrospective analysis compares the results of 52 (46%) of patients who continued at full dose Iressa with the 62 (54% (!!)) who had a dose-reduction of Iressa, generally switching to once every two day treatment (because there are no lower dose tablets of gefitinib than 250 mg). The analysis showed no significant difference at all in outcomes, and even a numerically longer median progression-free survival of 351 days vs. 301 days, and median overall survival of 928 days vs. 852 days, for the lower dose vs. full dose recipients, respectively. This doesn't mean that lower dosing is a superior strategy (these are not close to statistically significant differences, and the groups aren't huge), but it should allay anyone's fears that the people who need to reduce dose of their EGFR inhibitor due to challenging side effects are compromising their treatment -- at least for patients who have tumors with an EGFR mutation.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on